Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate parameters related to safety and efficacy of liraglutide in patients with type 2 diabetes and dialysis-dependent end-stage renal disease (ESRD). RESEARCH DESIGN AND METHODS: Twenty-four patients with type 2 diabetes and ESRD and 23 control subjects with type 2 diabetes and normal kidney function were randomly allocated to 12 weeks of double-blind liraglutide (titrated to a maximum dose of 1.8 mg) or placebo treatment (1:1) injected subcutaneously once daily as add on to ongoing antidiabetic treatment. Dose-corrected plasma trough liraglutide concentration was evaluated at the final trial visit as the primary outcome measure using a linear mixed model. RESULTS: Twenty patients with ESRD (1:1 for liraglutide vs. placebo) and 20 control subjects (1:1) completed the study period. Dose-corrected plasma trough liraglutide concentration at the final visit was increased by 49% (95% CI 6–109, P = 0.02) in the group with ESRD compared with the control group. Initial and temporary nausea and vomiting occurred more frequently among liraglutide-treated patients with ESRD compared with control subjects (P < 0.04). Glycemic control tended to improve during the study period in both liraglutide-treated groups as assessed by daily blood glucose measurements (P < 0.01), and dose of baseline insulin was reduced in parallel (P < 0.04). Body weight was reduced in both liraglutide-treated groups (−2.4 ± 0.8 kg [mean ± SE] in the group with ESRD, P = 0.22; −2.9 ± 1.0 kg in the control group, P = 0.03). CONCLUSIONS: Plasma liraglutide concentrations increased during treatment in patients with type 2 diabetes and ESRD, who experienced more gastrointestinal side effects. Reduced treatment doses and prolonged titration period may be advisable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Survival advantages of obesity in dialysis patients
Kalantar-Zadeh, K., Abbott, K. C., Salahudeen, A. K., Kilpatrick, R. D., & Horwich, T. B. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/81.3.543 · Cited by 610
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“Plasma liraglutide concentrations correlate with the frequency and intensity of AEs related to treatment with liraglutide (22), and elderly patients and patients with mild renal impairment are known to be more prone to its gastrointestinal side effects (13).”
BackgroundNeurological complications in renal failure: a review
Brouns, R., & De Deyn, P. P. (2004) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2004.07.012 · Cited by 392 · cited 1×
“risk of hypoglycemia is high, and unawareness, often associated with autonomous neuropathy, frequently further impedes insulin treatment in patients with ESRD and diabetes (6).”
BackgroundScheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102
Effects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97
Chatterjee, D. J., Khutoryansky, N., Zdravkovic, M., Sprenger, C. R., & Litwin, J. S. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009339189 · Cited by 54 · cited 1×
“trials with liraglutide, the trough value was estimated to be 20,000 pmol/L during steady state and the SD was estimated to be 8,000 pmol/L in people with normal kidney function (20,21).”
Background
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 226
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
“In contrast, however, in a study of subjects with type 2 diabetes and end-stage renal disease undergoing dialysis treatment, plasma liraglutide concentrations were higher than in subjects with type 2 diabetes and normal renal function [51].”
ResultGLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144
He, Z., Gao, Y., Lieu, L., Afrin, S., Cao, J., Michael, N. J., Dong, Y., Sun, J., Guo, H., & Williams, K. W. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.07.008 · Cited by 128
Safety of liraglutide in type 2 diabetes and chronic kidney disease
Mann, J. F. E., Fonseca, V. A., Poulter, N. R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., Mosenzon, O., & on behalf of the LEADER Trial Investigators (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11881019 · Cited by 50
Self-citationClemens, K. K., Ernst, J., Khan, T., Reichert, S., Khan, M. Q., LaPier, H., Chiu, M., Stranges, S., Sahi, G., Castrillon-Ramirez, F., et al. (2023) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.023 · Cited by 40
Orandi, B. J., Chen, Y., Li, Y., Charyton, D., Lentine, K. L., Lee, B. P., Ali, N., DeMarco, M. P., Weintraub, M. A., Bae, S., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000750 · Cited by 38
Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study
Wang, J., Huang, J., Li, W., Tang, S., Sun, J., Zhang, X., Liu, J., Yi, B., Liu, J., Zhang, X., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14091 · Cited by 16
Thomas, A. M., Lamb, K., & Howard, O. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.06.003 · Cited by 12
Metadata
- Authors
- Idorn, T., Knop, F. K., Jørgensen, M. B., Jensen, T., Resuli, M., Hansen, P. M., Christensen, K. B., Holst, J. J., Hornum, M., & Feldt-Rasmussen, B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-08-17
- Volume
- 39
- Issue
- 2
- Pages
- 206-213
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1934604330
- Cited by
- 96
- References
- 8
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.